Caribou Biosciences (CRBU) Depreciation & Amortization (CF) (2020 - 2026)
Caribou Biosciences (CRBU) posted quarterly Depreciation & Amortization (CF) of $649000.0 for Q1 2026, down 44.29% year-over-year from $1.2 million in Q1 2025, and down 4.84% quarter-over-quarter from $682000.0 in Q4 2025.
Caribou Biosciences (CRBU) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has reported Depreciation & Amortization (CF) for 7 consecutive years, with $649000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 44.29% year-over-year to $649000.0; the TTM figure through Mar 2026 stood at $3.1 million (down 28.59% YoY), while the FY2025 annual figure was $3.6 million, down 7.18% from the prior year.
- Depreciation & Amortization (CF) retreated to $649000.0 in Q1 2026 per CRBU's latest filing, from $682000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $1.6 million in Q3 2023 and bottomed at $308000.0 in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $786352.9 across 5 years, with a median of $682000.0 in 2025.
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) jumped 250.89% — and 2025, when it slumped 46.39%.
- Caribou Biosciences' Depreciation & Amortization (CF) stood at $506000.0 in 2022, then jumped by 46.25% to $740000.0 in 2023, then soared by 60.0% to $1.2 million in 2024, then plunged by 42.4% to $682000.0 in 2025, then slipped by 4.84% to $649000.0 in 2026.
- Business Quant data shows CRBU's Depreciation & Amortization (CF) at $649000.0 in Q1 2026, $682000.0 in Q4 2025, and $631000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Caribou Biosciences | 166.63 Mn | 54.31 Mn | - | 625,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 625,000.00 |
| Jun 30, 2026 | 625,000.00 |
| Mar 31, 2026 | 649,000.00 |
| Mar 31, 2026 | 649,000.00 |
| Dec 31, 2025 | 682,000.00 |
| Dec 31, 2025 | 682,000.00 |
| Sep 30, 2025 | 631,000.00 |
| Sep 30, 2025 | 631,000.00 |
| Jun 30, 2025 | 1.17 Mn |
| Jun 30, 2025 | 1.17 Mn |
| Mar 31, 2025 | 1.17 Mn |
| Mar 31, 2025 | 1.17 Mn |
| Dec 31, 2024 | 1.18 Mn |
| Dec 31, 2024 | 1.18 Mn |
| Sep 30, 2024 | 1.18 Mn |
| Sep 30, 2024 | 1.18 Mn |
| Jun 30, 2024 | 856,000.00 |
| Jun 30, 2024 | 856,000.00 |
| Mar 31, 2024 | 710,000.00 |
| Mar 31, 2024 | 710,000.00 |